Abstract
As genome editing rapidly progresses toward the realization of its clinical promise, assessing the suitability of current tools and processes used for its benefit-risk assessment is critical. Although current regulations may initially provide an adequate regulatory framework, improvements are recommended to overcome several existing technology-based safety and efficacy issues. As genome editing rapidly progresses toward the realization of its clinical promise, assessing the suitability of current tools and processes used for its benefit-risk assessment is critical. Although current regulations may initially provide an adequate regulatory framework, improvements are recommended to overcome several existing technology-based safety and efficacy issues.
Original language | English (US) |
---|---|
Pages (from-to) | 427-430 |
Number of pages | 4 |
Journal | Cell Stem Cell |
Volume | 21 |
Issue number | 4 |
DOIs |
|
State | Published - Oct 5 2017 |
Keywords
- benefit-risk assessment
- clinical trials
- efficacy
- genome editing
- off-target effects
- regulations
- safety
ASJC Scopus subject areas
- Molecular Medicine
- Genetics
- Cell Biology